Addiction: what’s new in 2023
Rev Med Suisse. 2024 Jan 17;20(856-7):12-14. doi: 10.53738/REVMED.2024.20.856-7.12. ABSTRACT Addiction medicine is currently facing new challenges, such as drug epidemics and open drug scenes. It...
Thermophysical properties of blends composed of Amazonian fats and soybean oil
Food Res Int. 2024 Feb;177:113911. doi: 10.1016/j.foodres.2023.113911. Epub 2023 Dec 22. ABSTRACT Thermophysical properties of blends composed of soybean oil and fats obtained from fruits...
A systematic review of analytical methodologies capable of analysing phytocannabinoids in cosmetics
Drug Test Anal. 2024 Jan 16. doi: 10.1002/dta.3628. Online ahead of print. ABSTRACT As cannabidiol (CBD) is not considered to be a drug and because...
Study on transcriptome characteristics of respiratory syncytial virus bronchiolitis in children by RNA sequencing
Zhonghua Yu Fang Yi Xue Za Zhi. 2024 Jan 6;58(1):71-80. doi: 10.3760/cma.j.cn112150-20230126-00057. ABSTRACT To explore the biological characteristics related to the pathogenesis and severity of...
Narrative bias (“spin”) is common in randomised trials and systematic reviews of cannabinoids for pain
Pain. 2024 Jan 11. doi: 10.1097/j.pain.0000000000003140. Online ahead of print. ABSTRACT We define narrative bias as a tendency to interpret information as part of a...
Levels and sources of polycyclic aromatic hydrocarbons (PAHs) near hospitals and schools using leaves and barks of Sambucus nigra and Acacia melanoxylon
Environ Geochem Health. 2024 Jan 16;46(2):32. doi: 10.1007/s10653-023-01825-z. ABSTRACT Polycyclic aromatic hydrocarbons (PAHs) are among the most studied organic compounds in urban environments, due to...
Cannabinoid treatment for the symptoms of autism spectrum disorder
Expert Opin Emerg Drugs. 2024 Jan 16. doi: 10.1080/14728214.2024.2306290. Online ahead of print. ABSTRACT INTRODUCTION: Autism spectrum disorder (ASD) is a neurodevelopmental disorder affecting approximately...
Cannabis Use and Perinatal Health
JAMA. 2024 Jan 16;331(3):256-257. doi: 10.1001/jama.2023.23236. NO ABSTRACT PMID:38227040 | DOI:10.1001/jama.2023.23236...
Alzheimer’s disease, aging, and cannabidiol treatment: a promising path to promote brain health and delay aging
Mol Biol Rep. 2024 Jan 16;51(1):121. doi: 10.1007/s11033-023-09162-1. ABSTRACT Alzheimer’s disease (AD) is the most common neurodegenerative disease characterized by progressive memory loss, neurodegeneration, and...
Insight into the mechanism of action of ORG27569 at the cannabinoid type one receptor utilising a unified mathematical model
Naunyn Schmiedebergs Arch Pharmacol. 2024 Jan 16. doi: 10.1007/s00210-023-02923-6. Online ahead of print. ABSTRACT Allosteric modulation of CB1 is therapeutically advantageous compared to orthosteric activation...
Alzheimer’s disease, aging, and cannabidiol treatment: a promising path to promote brain health and delay aging
Mol Biol Rep. 2024 Jan 16;51(1):121. doi: 10.1007/s11033-023-09162-1. ABSTRACT Alzheimer’s disease (AD) is the most common neurodegenerative disease characterized by progressive memory loss, neurodegeneration, and...
The efficacy of Omega-3 polyunsaturated fatty acids for severe burn patients: A systematic review and trial sequential meta-analysis of randomized controlled trials
Clin Nutr ESPEN. 2024 Feb;59:126-134. doi: 10.1016/j.clnesp.2023.11.019. Epub 2023 Dec 1. ABSTRACT BACKGROUND & AIMS: Severe burns lead to metabolic changes, systemic inflammatory response syndrome,...
The impact of cannabis on non-medical opioid use among individuals receiving pharmacotherapies for opioid use disorder: a systematic review and meta-analysis of longitudinal studies
Am J Drug Alcohol Abuse. 2024 Jan 15:1-15. doi: 10.1080/00952990.2023.2287406. Online ahead of print. ABSTRACT Background: The relationship between cannabis use and the risk of...
The Therapeutic Potential of Cannabidiol in Revolutionising Opioid Use Disorder Management
Cureus. 2023 Dec 16;15(12):e50634. doi: 10.7759/cureus.50634. eCollection 2023 Dec. ABSTRACT Opioid use disorder (OUD) is a significant cause of morbidity and mortality worldwide and is...
A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial
BMC Cancer. 2024 Jan 15;24(1):83. doi: 10.1186/s12885-023-11792-4. ABSTRACT BACKGROUND: Glioblastoma (GBM) is the most common adult malignant brain tumour, with an incidence of 5 per...